Abstract library

294 results for "markers".
#1032 Clinico-Biological and Histological Predictive Factors and Markers of Response to Everolimus in Neuroendocrine Tumors
Introduction: Several systemic treatments are available for metastatic neuroendocrine Tumors (NETs), including everolimus, but there is no predictive factor of response to these treatments.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Noura Benslama
#2870 When It Comes to the Diagnostic of Neuroendocrine Neoplasms (NEN), Not All Markers and Clones Were Made Equal. Assessment of 5 Makers in 466 NEN from 10 Anatomical Sites
Introduction: Histological diagnostic of neuroendocrine neoplasms (NEN) relies on morphological criteria and expression of several neuroendocrine marker assessed by immunohistochemistry. Systematic large evaluation of classical (chromogranin A (chrA), synaptophysin (Syn), CD56) and emerging (chromogranin B (chrB), INSM1) markers are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Dr Jerome Cros
Authors: Mamodaly M, Chen R, Cazes A, Guedj N, ...
#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results
Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Tahir Shah
Authors: Shah T, Caplin M, Khan M, Houchard A, ...
#2970 Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)
Introduction: Well-differentiated neuroendocrine tumors G3 (NETsG3) pts have a different biological behavior compared to those with neuroendocrine carcinomas (NECs). Sensitivity to platinum depends on Ki67 and there is no standard second line (2L). Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are predictive factors of cancer survival, but with limited evidence in NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Soledad Cameselle-Garcia
#281 Biochemical Markers in Diagnosis and Monitoring of Neuroendocrine Tumors
Introduction: The biochemical diagnosis and monitoring of neuroendocrine tumors is very important in the clinical management of patients.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Nina V. Lyubimova
#508 Differential Expression of Markers in a Midgut Carcinoid Tissue Microarray
Introduction: Molecular mechanisms driving well-differentiated midgut carcinoid (MGC) tumors are not well-established. To pursue higher resolution tumor diagnostics, we studied a panel of markers for their expression in MGC, including: serotonin, FGF2, b-catenin, and E-cadherin, in primary, lymph node, and liver metastases.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Eric Liu
Authors: Liu E, Mikhitarian K, Revetta F, Shi C, ...
#682 Neuroendocrine Tumors, Searching for New Prognostic Biomarkers
Introduction: Neuroendocrine tumors (NET) of the digestive system were once considered relatively rare, however, the incidence is increasing. New prognostic biomarkers are needed for assessment of tumor behavior to inform patient treatment and improve outcome. The proliferation marker, Ki-67, is used for NET grading. Although classified as low grade, some tumors actually develop metastases.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Helen Miller
#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET
Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Jerome Cros
Authors: Bucau M, Cros J, Raffenne J, Rebours V, ...
#582 Comparison of biomarkers in predicting presence and severity of carcinoid heart disease in patients with metastatic mid-gut neuroendocrine tumours
Introduction: Carcinoid heart disease (CHD) is evaluated using echocardiography. The utility of plasma biomarkers for detecting the presence/severity of CHD is under-explored.
Conference:
Category: Clinical
Presenting Author: Dr Rebecca Dobson
#2050 Finding the Ways to Determine the Prognosis of Pulmonary Carcinoids with Certain Genes/Markers in Pakistan
Introduction: Pulmonary neuroendocrine tumors are classified into four subtypes from well differentiated to poorly differentiated high grade large cell neuroendocrine carcinomas. Because of the difficult histological classification and a cancer free period following surgery, it is often difficult to predict certain prognostic factors.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...